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088: Novel paradigm in lipid metabolic network
of Mycobacterium tuberculosis
Tarun Chopra, Debasisa Mohanty, Rajesh S. Gokhale
National Institute of Immunology, Aruna Asaf Ali Marg, India
Mycobacterium tuberculosis (Mtb) is the etiologic agent of tuberculosis
and infects *32% of the human population. The cell envelope of
mycobacteria is endowed with a number of unique lipids that play an
important role in its virulence. Large multifunctional proteins called
polyketide synthases (PKSs) catalyze the biosynthesis of these lipids.
PKSs are generally involved in the synthesis of secondary metabolites
in various organisms and their role in biosynthesis of virulence factors is
unprecedented. PKSs require proteins called fatty acyl AMP ligases for
the activation and utilization of fatty acid substrates. PKS12 is the
largest open reading frame in the Mtb genome and contains at least
twelve different catalytic sites on a single protein. Our systematic
investigation of PKS12 protein revealed formation of a novel supra-
molecular assembly that catalyzes biosynthesis of a mycobacterial
phospholipid antigen. Clearly, the lipid repertoire of mycobacteria
necessitates a coordinated network of various biosynthetic enzymes.
Insights into these molecular events provide an opportunity to develop
inhibitors that would simultaneously disrupt several pathways in lipid
metabolism. Due to overlapping substrate specificities and cofactor
requirements of various enzymes involved in lipid biosynthesis,
directed synthesis of chemical compounds targeting multiple pathways
could provide new avenues for drug discovery.
089: A high-throughput generation of natural
product-inspired compounds: The discovery
of chemical modulators of cell death pathways
involving Bcl-XL/Mcl-1
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Bcl-2 is the founding member of a group of proteins that includes
anti-apoptosis proteins such as Bcl-2, Bcl-XL and Mcl-1 and pro-
apoptosis proteins such as Bax and Bak. Although Mcl-1 is a
homologous protein related to other anti-apoptotic proteins such as
Bcl-2 and Bcl-XL, it has a distinctly different structure and specificity
for its binding to other pro-death Bcl-2 members. Cancer cells that are
highly resistant to small-molecule inhibitors of Bcl-2/Bcl-XL can
become highly sensitive when Mcl-1 activity is eliminated by sRNAi,
indicating the critical importance of inhibiting both Mcl-1 and Bcl-
XL/Bcl-2 for successful chemotherapy. Targeting Mcl-1 is therefore
an important strategy in a search of a class of anticancer agents based
on overcoming the apoptosis resistance.
With the goals of identifying small molecule modulators of
protein-protein interactions, our group is developing high-throughput
methods leading to library generation of natural-product inspired
small molecules. In addition to testing these small molecules in
solution, they are also utilized in printing small molecule microchips
in collaboration with the Chemical Biology Program at the Broad
Institute. Through utilizing the small molecule microchip technology,
we identified a novel, natural product-inspired scaffold as a small
molecule binder to Mcl-1. This study then led us to initiating col-
laboration with the Gehring team to carry-out low-throughput
screening of several analogs as small molecule binders to Bcl-XL
and Mcl-1 by NMR using the fragment-based approach. This led us
to identify a novel chiral tetrahydroquinoline scaffold as a weak
binder 200 lM to both Bcl-XL and Mcl-1. To our delight, by simply
making only nine derivatives of this scaffold, we were able to dis-
cover the lead compound as a low uM binder to Mcl-1. Interestingly,
this compound also binds to Bcl-XL but with nearly threefold less
affinity.
090: Novel RNAi-based chemical genetic screen
to identify small molecule modulators of the Wnt/wg
signaling pathway
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Recent advances in functional and chemical genomics have led to vast
advances in both, the understanding of disease and the potential to
discover effective therapeutics to combat otherwise intractable dis-
ease states such as cancer. The Wnt/wingless (wg) pathway is one of a
core set of evolutionarily conserved signaling pathways that regulates
many aspects of development and homeostasis. Misregulation of the
Wnt pathway can be detrimental since mutations in several compo-
nents are associated with tumorigenesis of the breast, liver, colon, and
the skin. It is therefore crucial to develop and implement new tech-
nologies in order to generate molecular tools that may be used to
modulate the activity of the Wnt/wg signaling pathway. One of the
key effectors of the Wnt pathway is encoded by beta-catenin (B-cat).
Induction by Wnt ligands leads to stabilization of cytosolic B-cat,
which subsequently translocates to the nucleus to activate target genes
that regulate many aspects of cell proliferation, growth, differentia-
tion and death. Since Catenin Responsive Transcription (CRT) has
been implicated in the genesis of many cancers, it makes a good target
for developing therapeutics that could modulate the nuclear activity of
B-cat. Recently, we employed a novel methodology of integrating a
‘sensitized’ chemical genetic high-throughput screen (HTS) with
RNA-interference (RNAi) screening technology in order to identify
specific small molecule inhibitors of the Wnt pathway in Drosophila
cells. The primary screen was performed in Drosophila derived Clone
8 cells, which afforded the advantage of a non-redundant genome.
Subsequent secondary screens were performed in mammalian cell
lines including the mouse mammary epithelial cell line, C57 mg;
human epithelial cell line, HEK 293; the colon-cancer cell line, HCT-
116; and the breast cancer cell line, MCF-7. Each of the aforemen-
tioned cell types is Wnt responsive and thus allowed for heterologous
systems to validate the efficacy of the compounds on Wnt-signaling.
We envisage that compounds identified in ours and similar future
screens will serve as prototypes for the development of anti-tumor
drugs targeted to B-cat responsive transcriptional programs involved
in different cancers. Furthermore, this study paves the way for the
development and implementation of a new technological advance for
rapid screening of large compound libraries to identify modulators of
specific signaling pathways.
091: Application of small molecule screening
to investigate binding specificity of protein families
Masoud Vedadi, Guillermo Senisterra, Gregory Wasney,
Abdellah Allali-Hassani, Patrick Finerty, Aled Edwards,
Cheryl Arrowsmith
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Availability of a generic screening method, which is not dependent on
the activity of proteins and can rapidly identify small molecules that
interact with proteins, greatly facilitates analysis of the binding
specificity of individual members of any family of proteins. We have
employed various high throughput small molecule screening methods
to investigate the binding specificity of different members of families
of human proteins such as kinases and sulfotransferases. These
methods include differential static light scattering (DSLS), a label
free method, and differential scanning fluorimetry (DSF), a fluores-
cence based method. Creating chemical fingerprints for each protein
provides the opportunity to compare the small molecule binding
specificity of different members of each family and enables us to
identify potential inhibitors that bind to only a subset of proteins
and discriminate between different members. Using DSLS we have
also screened three membrane proteins: ABC transporter MsbA,
Mg++ channel CorA and histidine kinase CpxA, and detected the
stabilizing effect of some ligands. We identified ligands, including
ATP and its analogues, for MsbA by screening it against a library of
38 selected compounds and also detected the binding of Mg++ and
ADP to CorA and CpxA, respectively. Combination of these available
techniques provide an opportunity to investigate protein-ligand
interaction genome-wide.
092: The effects of humanin peptides on mitochondrial
functions and global gene expression
Marek Bodzioch, Katarzyna Lapicka-Bodzioch, Barbara Zapala,
Aldona Dembinska-Kiec
Department of Clinical Biochemistry, Collegium Medicum,
Jagiellonian University, Kopernika 15a, 31501 Krakow, Poland
Backgroud: Humanin (HN) is a novel antiapoptotic and neuropro-
tective peptide. Using bioinformatic tools, we have recently identified
a host of putative nuclearly-encoded HN peptides.
Aim: To assess the biological properties of the synthetic nuclear HN
peptides.
Methods: Human umbilical vein endothelial cells (HUVECs) were
exposed to proapoptotic conditions triggering the BAX-related path-
ways (staurosporine or UV light) and incubated with different HN
peptides. Global gene expression changes were assessed by custom-
made Affymetrix NuGO chips, while mitochondrial function and
apoptosis were monitored in real-time by high-throughput fluores-
cence confocal microscopy (BD Pathway Bioimager 855) using
markers of viable mitochondria (TMRM, JC-1) and active caspases
(specific labeled antibodies).
Results: Among the studied peptides, significant differences in anti-
apoptotic potential were found between the Thr13 and Ile13 izoforms
(c.38C [ T) of the HN10b. The wild-type threonine izoform provided
much stronger antiapoptotic activity then the isoleucine peptide.
HUVECs treated with Ile13 HN10b succumbed significantly quicker
to staurosporine than those pre-incubated with Thr13 HN10b as
demonstrated by the rate of TMRM signal loss paralleled by the
increase in caspase activation. Variable functional properties of the
Thr13 and Ile13 HN10b variants were also reflected by differential
global gene expression patterns.
Conclusion: The nuclearly-encoded HN peptides may differ in their
antipoptotic potential, which is especially apparent when comparing
the Thr13 and Ile13 variants of HN10b.
093: S29 ribosomal protein regulates balance between
cell death and survival in Hep2 cells through MAPK/
mitochondrial pathway
1Jyoti Balhara, 1Ravindresh Chhabra, 1Yogita Malik, 1Richa Singh,
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Multifunctionality of proteins is one of the mechanisms accounting
for the complexity of interactome networks in higher eukaryotes.
There are various reports in the literature which suggest that during
oncogenesis and other pathologic conditions many proteins perform
additional functions without changes in three dimensional structures.
One such multifunctional protein is S29 ribosomal protein. The S29
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ribosomal protein is not only involved in ribosome assembly but its
enhanced expression has been shown to possess antitumor properties
in non small cell lung cancer H520 cells. Literature also suggest that
S29 ribosomal protein increases tumor suppressor activity of RAP1A
(Krev-1) gene on v-K ras-transformed NIH3T3 cells. Recently con-
servation and multifunctional nature of ribosomal protein S29 has
considerably drawn the attention of researchers so that basic mech-
anism behind its function can be elucidated. Adopting biochemical
and proteomic approaches we made an attempt to investigate the
antiproliferative potential of S29 ribosomal protein on cultured Hep2
cells. Apoptosis was examined by Hoechst 33342 staining, FACS,
increased expression of pro-apoptotic protein Bax, decreased
expression of anti-apoptotic proteins Bcl-2 and Bcl-XL, release of
apoptogenic cytochrome c and activation of initiator caspase-8, -9 and
effector caspase-3 followed by cleavage of nuclear substrate poly
(ADP-ribose) polymerase. There was also non-involvement of p53 in
S29 ribosomal protein induced apoptosis and the pro-apoptotic effect
was mediated by inactivation of ERK, JNK and p38 MAPK. We
further assessed whether S29 overexpression could increase chemo-
sensitivity of cancer cells to chemotherapeutic agents. Our results
showed that S29 overexpression increases Hep2 cells sensitivity to
Cisplatin, Etoposide and TNF alpha; but to different extents. Our
proteomic results also confirmed the proapoptotic role of S29. For the
first time, we report here the potential of anti-human laryngeal
activity of S29 ribosomal protein in Hep2 cells. This study also raises
the possibility of S29 ribosomal protein as a promising approach to
cancer therapy.
094: Novel neurotrophic factors for the treatment
of neurodegenerative diseases
Mart Saarma
Institute of Biotechnology, University of Helsinki, Finland
Neurotrophic factors (NTF) are small secretory proteins that promote
differentiation and maintenance of neurons in developing and adult
vertebrate nervous system. NTFs can also protect degenerating neu-
rons in neurodegenerative diseases. In Parkinson’s disease there is a
progressive loss of functional dopaminergic neurons projecting from
substantia nigra to caudate putamen. The most potent NTF, the glial
cell line-derived neurotrophic factor (GDNF) delivery into the puta-
men of Parkinsonian patients has resulted in significant clinical
improvement in some patients, but in double-blind clinical trial no
symptomatic improvement compared to placebo was reported. We
have identified a novel survival factor for dopaminergic neurons, the
conserved dopamine neurotrophic factor (CDNF), which was strongly
neuroprotective and neurorestorative in an experimental model of
Parkinson’s disease in rats. CDNF is a secreted protein with eight
conserved cysteine residues with the unique protein fold and defining
a novel, evolutionarily conserved neurotrophic factor family. Other
members of this family include the mesencephalic astrocyte-derived
neurotrophic factor (MANF) and invertebrate MANFs. Our results
demonstrate that CDNF might be beneficial for the treatment of
Parkinson’s disease.
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